November 18, 2020
Article
Dr. Anthony Fauci discusses the cardiovascular implications of coronavirus disease 2019 (COVID-19) at the American Heart Association Scientific Sessions.
November 17, 2020
After recent setbacks, the beleaguered drug reduced cardiovascular events and may be a choice for patients with severe chronic kidney disease.
November 15, 2020
The investigator of the STRENGTH study says findings raise questions about the landmark REDUCE-IT trial, but other evidence suggests the drugs involved are different.
November 13, 2020
A registry study suggests 4 in 5 patients with heart failure might benefit from the SGLT2 inhibitor dapagliflozin.
Findings from the GALACTIC-HF trial presented at AHA Scientific Sessions 2020 showed that patients with heart failure (HF) with reduced ejection fraction who took omecamtiv mecarbil showed a significant 8% relative risk reduction in a composite of a HF event or death from cardiovascular causes, compared with those taking placebo.
January 31, 2020
Video
The GUARD-AF trial will allow us to look at both the benefits and the risks of screening for atrial fibrillation and the reduction of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.
January 26, 2020
We are really excited about the progress we have seen in the EXPLORER-HCM trial, and after the results are published in the first half of 2020, we will quickly begin conversations to seek FDA approval of mavacamten, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.
January 16, 2020
Results of the PIONEER-OLE study has shown promising results of mavacamten for patients with obstructive HCM that will be further evaluated in our pivotal phase 3 EXPLORER-HCM trial, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.
January 11, 2020
There are multiple ways in which people with diabetes can develop heart failure, which is why heightened awareness through the initiative Diabetes Can Break Your Heart is warranted, said Javed Butler, MD, MPH, MBA, professor of physiology and chairman for the Department of Medicine at the University of Mississippi.
January 03, 2020
The phase 2 ESCaPE-CMD study results exhibited a significant improvement in coronary flow reserve for patients with CMD, said C. Noel Bairey Merz, MD, FACC, FAHA, director of the Barbra Streisand Women's Heart Center.
